نتائج البحث

Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

• Authors : National Center for Advancing Translational Sciences (NCATS)

• Source: Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

تفاصيل العنوان

Evaluation of a Personalised Survivorship Care Plan App for Patients with Melanoma (Melanoma SCP)

• Authors : BeterKeten; Albert Schweitzer Hospital; Maasstad Hospital ...

• Source: Personalised Survivorship Care for Patients with Melanoma: a Multicenter Randomised Controlled Trial of the Survivorship Care Plan App

تفاصيل العنوان

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

• Source: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma

تفاصيل العنوان

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)

• Authors : Ono Pharmaceutical Co. Ltd

• Source: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in

تفاصيل العنوان

Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families

• Authors : National Cancer Institute (NCI); Sharon Manne, PhD, Professor of Medicine

• Source: Facebook Intervention for Young Onset Melanoma Patients and Families

تفاصيل العنوان

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

• Source: A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for Nivolumab + Relatlimab Fixed-dose Combination Subcutaneous Versus Nivolumab + Relatlimab Fixed-dose Combination Intravenous

تفاصيل العنوان

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

• Source: A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects

تفاصيل العنوان

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

• Source: A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic

تفاصيل العنوان

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

• Source: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV

تفاصيل العنوان

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

• Authors : Clinigen, Inc.

• Source: A Phase II Study of High Dose Bolus IL2 in Combination With Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients With Inoperable Stage III or Stage IV

تفاصيل العنوان